SINGLE-DOSE DACARBAZINE AND DACTINOMYCIN IN ADVANCED MALIGNANT-MELANOMA

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (1) , 39-42
Abstract
Patients (21) with advanced malignant melanoma were treated with dacarbazine at a dose of 800 mg/m2 as a single infusion and dactinomycin at a dose of 1.2 mg/m2 every 3 wk. Hematologic toxicity was mild and gastrointestinal toxicity was tolerable. The response rate for evaluable patients was 22%, which included both men and women with visceral disease. Three of the 4 responses were complete. Durations of response were 4, 6, 9 and 48 .+-. mo. Dacarbazine evidently can be safely and effectively given as a single dose along with dactinomycin. This combination could be more effective than single agents in obtaining complete responses in patients with visceral disease.